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Proteasome impairment in neural cells
derived from HMSN-P patient iPSCs
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Abstract
Hereditary motor and sensory neuropathy with proximal dominant involvement (HMSN-P) is caused by a
heterozygous mutation (P285L) in Tropomyosin-receptor kinase Fused Gene (TFG), histopathologically characterized by
progressive spinal motor neuron loss with TFG cytosolic aggregates. Although the TFG protein, found as a type of
fusion oncoprotein, is known to facilitate vesicle transport from endoplasmic reticulum (ER) to Golgi apparatus at ER
exit site, it is unclear how mutant TFG causes motor neuron degeneration. Here we generated induced pluripotent
stem cells (iPSCs) from HMSN-P patients, and differentiated the iPSCs into neural cells with spinal motor neurons
(iPS-MNs). We found that HMSN-P patient iPS-MNs exhibited ubiquitin proteasome system (UPS) impairment, and
HMSN-P patient iPS-MNs were vulnerable to UPS inhibitory stress. Gene correction of the mutation in TFG using the
CRISPR-Cas9 system reverted the cellular phenotypes of HMSN-P patient iPS-MNs. Collectively, these results suggest
that our cellular model with defects in cellular integrity including UPS impairments may lead to identification of
pathomechanisms and a therapeutic target for HMSN-P.
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Introduction
Hereditary motor and sensory neuropathy with proximal
dominant involvement (HMSN-P) is an autosomal-
dominant disease first described in patients from the
Okinawa Islands of Japan [1]. The clinical manifestation
of HMSN-P is characterized by late-onset progressive
muscle weakness of proximal limbs with widespread fas-
ciculations, shared with those of amyotrophic lateral
sclerosis (ALS), and the patients eventually require artifi-
cial ventilation due to respiratory failure [2, 3]. The
neuropathological findings of severe neuronal loss and
gliosis in the spinal anterior horns and nuclei of the
brainstem were reported, and as in ALS, ubiquitinated
aggregates in the cytoplasm of surviving spinal motor
neurons (MNs) were observed in HMSN-P [4]. A het-
erozygous mutation (P285L) in Tropomyosin-receptor
kinase Fused Gene (TFG) was identified as the gene re-
sponsible for HMSN-P, and the pathological hallmark of
HMSN-P is the formation of cytosolic inclusions of TFG
protein in spinal MNs [5].
TFG forms octamers that facilitate the co-assembly of
SEC 16 and COP II and work as a scaffolding protein to
support vesicle trafficking from endoplasmic reticulum
(ER) to Golgi apparatus at ER exit sites in various tissues
including brain and spinal cord [6–8]. TFG mutations
are related to various other neurodegenerative diseases
besides HMSN-P. Homozygous TFG R106C mutation
was identified in hereditary spastic paraplegia [9], and
heterozygous TFG G269V mutation was found in
Charcot-Marie-Tooth disease type 2 (CMT2) [10].
TFG P285L mutation is a heterozygous mutation lo-
cated in the proline/glutamine (P/Q)-rich domain, which
is essential for protein-to-protein interaction, and gains
of toxic TFG functions in the region may be associated
with progressive spinal MN degeneration. However, the
mechanisms of how mutant TFG (mt TFG) contributes
to MN degeneration in HMSN-P have not been eluci-
dated. Recent developments in induced pluripotent stem
cell (iPSC) technology [11] and the gene editing* Correspondence: haruhisa@cira.kyoto-u.ac.jp
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technique with the clustered regularly interspaced short
palindromic repeat (CRISPR) and CRISPR associated 9
(Cas9) endonuclease systems [12] enable us to model neur-
onal disease and investigate the cellular phenotypes of neu-
rons with the patient genetic background in vitro [13–15].
Here we generated iPSCs from HMSN-P patients and
differentiated the iPSCs into spinal MNs. We found that
HMSN-P patient spinal MNs presented ubiquitin
proteasome system (UPS) impairment and cellular
vulnerability. Gene correction of TFG P285L mutation
by CRISPR-Cas9 restored these cellular phenotypes.
Results
Generation of HMSN-P patient iPSCs and spinal MN
differentiation
We generated iPSCs from healthy control subjects and
HMSN-P patients with TFG P285L mutation (Table 1,
Additional file 1: Figure S1A). The generated iPSCs
expressed pluripotent stem cell markers (Fig. 1a). The glo-
bal gene expression profiles of control and HMSN-P pa-
tient iPSCs were comparable to human embryonic stem
cells (ESCs) and differed from somatic cells. We analyzed
mRNA expression levels of each of the iPSC clones using
RNA-seq analysis, and confirmed that the significant dif-
ferences were not observed among iPSCs generated from
human dermal fibroblasts (HDFs) and iPSCs generated
from peripheral blood mononuclear cells (PBMCs) (Add-
itional file 1: Figure S1B), as shown previously [16]. Pluri-
potency of each iPSC clone was confirmed by in vitro
three-germ layer assay (Additional file 1: Figure S1C).
These iPSCs were differentiated into spinal MNs by
serum-free floating culture of embryoid body-like
aggregates with quick re-aggregation (SFEBq) method
[17, 18]. There were no significant differences between
control and HMSN-P in their differentiation capacity
into spinal MNs and glial cells (Fig. 1a–e). We analyzed
the cellular phenotypes of HMSN-P using these iPSC-
derived neural cells with spinal MNs (iPS-MNs).
HMSN-P patient iPS-MNs exhibited UPS impairment and
vulnerability
According to the findings in postmortem tissue from a
HMSN-P patient, TFG aggregates were accumulated in
spinal MNs [5], forecasting impairment of UPS [19]. We
investigated whether HMSN-P patient iPS-MNs exhib-
ited TFG aggregates. To evaluate the aggregation of
TFG protein, we measured the area of TFG puncta in
SMI-32-positive neurons, and dot-like TFG puncta were
detected in both control and HMSN-P patient SMI-32-
positive neurons. The area of TFG puncta did not differ
between control and HMSN-P (Additional file 2: Figure
S2A, 2B), although there was a trend toward a larger
area of TFG puncta in HMSN-P patient SMI-32-positive
neurons. In some neurodegenerative disease models
using iPSCs, it is required to provide cellular stress so as
to recapitulate disease phenotypes such as accumulation
of pathological proteins and cell death [20]. As a cellular
stress, to remove trophic supports from surrounding
cells including glial cells to spinal MNs, we purified
spinal MNs labeled with lentivirus vector expressing
green fluorescent protein (GFP) under control of HB9
promoter (HB9::GFP) [21], and succeeded in finding
TFG aggregates in spinal MNs. The area of TFG aggre-
gates increased significantly in HMSN-P-patient purified
MNs compared to controls (Fig. 2a, b), although TFG
aggregates in HMSN-P patient purified MNs were not
increased significantly when purified MNs were co-
cultured with glial cells (Additional file 2: Figure S2C,
2D). These TFG aggregates were not merged with ubi-
quitin (Additional file 2: Figure S2E). Next, we evaluated
Table 1 Characteristics of iPSC clones
control1 control2 control3 HMSN-P1 HMSN-P2 HMSN-P3
Clone name at establishment TIG107 HC2EL5 hc3NORA ALS43EL1 ALS44E1 ALS44E9
Control or HMSN-P control control control HMSN-P HMSN-P
Gender female male female male female
Age at biopsy 81 64 65 48 52
Disease duration N.A. N.A. N.A. 5 years 12 years
Proximal muscle weakness N.A. N.A. N.A. + +
Bulbar symptoms N.A. N.A. N.A. - -
Respiratory failure N.A. N.A. N.A. - -
Sensory disturbance N.A. N.A. N.A. + +
Genotype N.A. N.A. N.A. TFG (P285L) TFG (P285L)
Origin HDFs PBMCs PBMCs HDFs HDFs
Reprogramming retrovirus episomal episomal episomal episomal
HMSN-P hereditary motor and sensory neuropathy with proximal dominant involvement, HDFs human dermal fibroblasts, PBMCs peripheral blood mononuclear
cells, iPSC induced pluripotent stem cell, N.A. not applicable
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the protein levels of TFG without additional cellular
stress. Immunoblot analysis of iPS-MNs showed the
TFG protein level to be significantly increased in
HMSN-P compared to controls (Fig. 2c, d). These results
demonstrated that TFG protein levels were increased in
HMSN-P, and that additional cellular stress accelerated
TFG aggregations.
Accumulation of aberrant protein is caused by dys-
function of protein degradation systems such as UPS
[22]. We measured UPS activity of iPS-MNs, and found
that UPS activity was impaired in HMSN-P compared to
control (Fig. 2e). Ubiquitinated proteins were increased
in HMSN-P, showing accumulation of high molecular
weight (HMW) proteins as detected by anti-ubiquitin
antibody (Fig. 2f, g). These results suggest that HMSN-P
patient iPS-MNs exhibited UPS dysfunction.
To investigate the association of UPS impairment with
spinal MN vulnerability, we evaluated spinal MN sur-
vival. In a culture duration of as long as 3 months, we
could not detect any vulnerability of HMSN-P patient
Fig. 1 Generation of iPSCs and spinal MN differentiation. a iPSCs were generated from healthy control individuals and HMSN-P patients with TFG
P285L mutation. Control and HMSN-P patient iPSCs were morphologically identical to human ESCs and expressed the pluripotent stem cell markers
NANOG and SSEA4. Nucleus was stained with DAPI. Scale bars = 200 μm. Differentiated MNs were stained with neuronal marker βIII-tubulin, MAP2,
and spinal MN marker SMI-32. Glial cells were stained with GFAP. Scale bars = 50 μm. b - e Proportions of control and HMSN-P patient neurons stained
positive for βIII-tubulin (b), MAP2 (c), SMI-32 (d), and GFAP (e) (n = 3, n.s. by Student t-test). There were no significant differences between control and
HMSN-P groups. Error bars are ± s.e.m., n.s.: not significant
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iPS-MNs compared to control. Clinically, the onset of
HMSN-P is after middle age [1]. It may be needed cellu-
lar stress as shown in aging process to detect vulnerabil-
ity of HMSN-P patient iPS-MNs. It is reported that UPS
impairment progresses according to aging [23]. There-
fore, we added proteasome inhibitor MG132 as a stress
inducer to enhance UPS impairment in order to examine
whether HMSN-P patient iPS-MNs presented neuronal
vulnerability. The number of surviving HMSN-P patient
iPS-MNs was significantly decreased by MG132 expos-
ure compared to controls (Fig. 2h). Immunoblot analysis
showed that the level of cleaved caspase-3 was increased
in HMSN-P patient iPS-MNs after MG132 exposure
(Fig. 2i). We also confirmed the vulnerability using
another specific proteasome inhibitor, bortezomib
(Additional file 3: Figure S3). These data suggest that
HMSN-P patient iPS-MNs are vulnerable under UPS in-
hibitory stress in comparison to control.
Correction of TFG P285L mutation ameliorated cellular
phenotypes of HMSN-P patient iPS-MNs
To determine whether the phenotypes we observed in
HMSN-P patient iPS-MNs were dependent on the TFG
P285L mutant allele, we applied CRISPR-Cas9 mediated
gene targeting strategy to correct the mutation in a
HMSN-P patient iPSC clone, HMSN-P1. The process of
targeted gene correction is illustrated in Fig. 3a. We
seamlessly generated TFG P285L mutation-corrected
HMSN-P patient iPSCs (corrected) according to previ-
ous reports [24]. Targeted gene correction was
Fig. 2 Cellular phenotypes in HMSN-P patient iPS-MNs. a Immunostaining for TFG in purified MNs by HB9::GFP sorting. Scale bar = 10 μm.
b Quantification of area of TFG-positive puncta in purified MNs by HB9::GFP sorting measured by high-content analysis (n = 3, *p < 0.05 by Student
t-test). Error bars are ± s.e.m. c Immunoblot analysis of TFG in control and HMSN-P patient iPS-MNs. β-actin was used as loading control.
d Quantification of the TFG protein levels in control and HMSN-P patient iPS-MNs (n = 3, *p < 0.05 by Student t-test). e Proteasome activity of
control and HMSN-P patient iPS-MNs (n = 3, *p < 0.05 by Student t-test). Error bars are ± s.e.m. f Immunoblot analysis of ubiquitinated proteins in
control and HMSN-P patient iPS-MNs. β-actin was used as loading control. g Quantification of the level of HMW ubiquitinated proteins in control
and HMSN-P patient iPS-MNs (n = 3, *p < 0.05 by Student t-test). Error bars are ± s.e.m. h Survival of control and HMSN-P patient iPS-MNs after
MG132 exposure (n = 3, ** p < 0.01, by Student t-test). i Immunoblot analysis of cleaved caspase-3 in control and HMSN-P patient iPS-MNs
exposed to vehicle or MG132. β-actin was used as loading control. DMSO: dimethyl sulfoxide
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confirmed by restoration of the original intron 7 and
exon 8 without any exogenous sequence by DNA
sequencing (Fig. 3b).
We differentiated mutation-corrected iPSCs into
spinal MNs, and found that the area of TFG aggregates
in the mutation-corrected purified MNs decreased sig-
nificantly compared to HMSN-P patient purified MNs
(Fig. 3c, d). The TFG protein levels were decreased by
the gene correction detected by immunoblot analysis
(Fig. 3e). UPS activity in HMSN-P was significantly
recovered by the gene correction (Fig. 3f ). Survival of
iPS-MNs after MG132 exposure was significantly
increased (Fig. 3g), and the level of cleaved caspase-3
was decreased (Fig. 3h) by the gene correction. These
data proved that TFG P285L mutation caused the
HMSN-P cellular phenotypes associated with UPS
impairment.
Discussion
We presented cellular phenotypes associated with the
UPS impairment of HMSN-P patient iPS-MNs, and
showed that gene correction of TFG P285L mutation
ameliorated the mt TFG-associated cellular phenotypes.
Fig. 3 Gene correction of TFG P285L mutation and improvement of cellular phenotypes in HMSN-P. a Gene targeting strategy used to generate
mutation-corrected iPSC clone. CRISPR-Cas9 targeting the TFG locus created a double strand break upstream of exon 8. Homologous recombination of
the genomic locus with a targeting plasmid with control sequence of exon 8 coupled puroΔTK replaced the TFG P285L mutant allele. After puromycin
selection, the resistance cassette was removed by transposon expression and FIAU selection. DSB: double strand break, FIAU: 1-(2-Deoxy-2-fluoro-β-D-
arabinofuranosyl)-5-iodouracil. b Sequencing of exon 8 of TFG in mutation-corrected iPSCs showed the correction of the TFG P285L mutation.
c Immunostaining for TFG in purified MNs by HB9::GFP sorting. Scale bar = 10 μm. d Quantification of area of TFG-positive puncta in purified MNs by
HB9::GFP sorting measured by high-content analysis (n = 9, **p < 0.01, one-way ANOVA followed by Tukey’s multiple comparison post hoc test). Error
bars are ± s.e.m. e Immunoblot analysis of TFG in control, HMSN-P patient, and mutation-corrected iPS-MNs. β-actin was used as loading control.
f Proteasome activity in control, HMSN-P patient, and mutation-corrected iPS-MNs (n = 3, * p < 0.05, one-way ANOVA followed by Tukey’s multiple
comparison post hoc test). Error bars are ± s.e.m. g Survival of control, HMSN-P patient, and mutation-corrected iPS-MNs after MG132 exposure
(n = 3, **p < 0.01, one-way ANOVA followed by Tukey’s multiple comparison post hoc test). Error bars are ± s.e.m. h Immunoblot analysis of cleaved
caspase-3 in control, HMSN-P patient, and mutation-corrected iPS-MNs after exposure of vehicle or MG132. DMSO: dimethyl sulfoxide
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UPS is a major pathway for the protein degradation
system to handle neurodegeneration-related proteins [22].
UPS dysfunction in 26S proteasome-mediated protein
clearance [25] and aberrant accumulation of ubiquitinated
proteins in neurodegenerative diseases including prion dis-
ease, Alzheimer’s disease, and ALS are reported [26–28].
In prion disease, prion protein binds directly to 20S core
components in the proteasome, interferes with gate open-
ing for substrate entry that leads to defects of peptide
hydrolysis, and impairs proteasomal degradation of
ubiquitinated proteins [26]. Tau protein, accumulated in
Alzheimer’s disease brain, also directly binds to 20S core
components and inhibits UPS activity [27]. TDP-43, a MN
disease-relevant protein, impairs UPS activity, although de-
tails of the mechanism for this are unknown [28]. Our
findings of UPS impairment in HMSN-P are consistent
with other neurodegenerative diseases. A mt TFG-
overexpressing cellular model showing impairment of UPS
[29] supports our findings. However, it is unclear how mt
TFG causes UPS impairment. We speculate that mt TFG
may possess direct or indirect inhibitory effects on UPS as
well as other neurodegenerative diseases [19, 30]. On the
other hand, we revealed that UPS impairment was ob-
served without TFG aggregates in our experiments. TFG
aggregates may not be essential for UPS impairment-
associated pathomechanisms. Further investigations for
the elucidation of the mechanisms of how mt TFG con-
tributes to the impairment of UPS activity are needed.
Our iPSC models have the advantage of obtaining data
from living human neurons without gene overexpres-
sion. We proved the decrease of UPS activity in HMSN-
P patient neural cells generated from iPSCs directly.
These findings were supported by a previous report
using cancer cell lines overexpressing mt TFG indicated
UPS dysfunction. Our data are important for providing
evidence using human patient neural cells. Furthermore,
since we should carefully consider and minimize clonal
variations for disease modeling with iPSCs [31–33], we
generated mutation-corrected isogenic control iPSCs,
and used not only healthy control iPSCs but also iso-
genic control iPSCs for disease modeling, and confirmed
that the observed cellular phenotypes were caused by
the TFG mutation.
In conclusion, we found UPS impairment as the
distinctive neural phenotypes of HMSN-P using patient
iPSCs. Our findings suggest that this cellular model may
contribute to elucidation of the disease pathomechan-




HDFs or PBMCs from healthy control subjects and
HMSN-P patients were reprogrammed by introducing
the episomal vectors with OCT3/4, SOX2, KLF4, L-
MYC, LIN28, and p53 carboxy-terminal dominant-
negative fragment as previously described [34]. Estab-
lished iPSCs were grown under feeder-free conditions
on laminin-511 E8 (Nippi, Tokyo, Japan) -coated plates
with StemFit AK03N (Ajinomoto, Tokyo, Japan) [35].
Another human iPSC clone, TIG107 [17], was added to
the control iPSC group.
Genotyping of TFG
Genotyping of TFG single nucleotide mutation was per-
formed by PCR amplification of genomic DNA and dir-
ectly sequenced (3500xL Genetic Analyzer, Applied
Biosystems, Waltham, MA).
RNA-seq analysis
Total RNA was extracted by RNeasy Mini Kit (Qiagen,
Venlo, Netherlands), and strand-specific cDNA libraries
were prepared using the TruSeq Stranded mRNA kit on
a NeoPrep system (Illumina, San Diego, CA) according
to the manufacturer’s instructions. The resulting libraries
were sequenced (75 bp single-end) on a NextSeq 500
system (Illumina). The sequenced reads were mapped to
the human reference genome (hg38) using tophat-2.1.0
with the aligner Bowtie2-2.2.5 [36, 37] after trimming
adaptor sequences and low-quality bases by cutadapt-
1.8.1 [38]. The number of reads mapped to each gene
was counted by HTSeq-0.6.1 software [39], and then
normalized with the DESeq2 R/Bioconductor package (v.
1.12.3) [40]. Hierarchical clustering analysis was
performed using R software version 3.3.1.
In vitro three-germ layer assay
iPSCs were dissociated with a cell scraper and used for
embryoid body (EB) formation. Clumps of cells were
transferred to suspension plates in Dulbecco’s modified
Eagle’s medium/Ham’s F12 (DMEM/F12, Sigma-Aldrich,
St.Louis, MO) containing 20% knockout serum replace-
ment (KSR, Life Technologies, Waltham, MA), 2 mM L-
glutamine, 0.1 mM nonessential amino acids (NEAA,
Invitrogen, Waltham, MA), 0.1 mM 2-mercaptoethanol
(2-ME, Life Technologies), and 0.5% penicillin and
streptomycin. The medium was changed every other day.
On Day 8, EBs were plated onto gelatin-coated plates and
allowed to differentiate for an additional 8 days.
Spinal MN differentiation from iPSCs
Induction of spinal MN differentiation from iPSCs was
performed as previously described [17, 18]. Briefly, iPSCs
were dissociated to single cells and quickly re-aggregated
in U-bottom 96-well plates for suspension culture
(Greiner Bio-One, Frickenhausen, Germany), pre-coated
with 2% Pluronic (Sigma-Aldrich) in 100% ethanol.
Aggregated EBs were cultured in 5% DFK medium
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[DMEM/F12 (Sigma-Aldrich), 5% KSR (Gibco,
Waltham, MA), 0.1 mMNEAA (Invitrogen), 2 mM L-glu-
tamine (Sigma-Aldrich), 0.1 mM 2-ME (Invitrogen)]
with 2 μM dorsomorphin, 10 μM Y27632 (Wako Chemi-
cals, Osaka, Japan), 10 μM SB431542 (Wako Chemicals),
3 μM CHIR99021 (Axon Medchem, Groningen,
Netherlands), and 12.5 ng/ml bFGF (Wako Chemicals)
for 4 days. On Day 4, 100 nM retinoic acid (Sigma-
Aldrich) and 0.5 μM Smoothened ligand (Enzo Life
Science, Farmingdale, NY) were added to the 5% DFK
medium. On Day 11, EBs were cultured in neurobasal
medium (Life Technologies) supplemented with 2%
B27 without vitamin A (Life Technologies), and 100
nM retinoic acid, 0.5 μM Smoothened ligand, and
10 μM DAPT (Sigma-Aldrich) were added to a sus-
pension culture plate. They were separated from the
dish by Accutase (Nacalai Tesque, Kyoto, Japan),
dissociated into a small clump or single cells, and
plated at 5.0 x 105cells per well onto Matrigel
(Corning, Tewksbury, MA) -coated 24-well plates on
Day 16, and then cultured for 2 weeks.
Immunocytochemistry
Plated cells were fixed in 4% paraformaldehyde in
phosphate-buffered saline (PBS) for 30 min. Cells were
washed three times with PBS after each step and then
blocked with 5% bovine serum albumin (Nacalai Tesque)
for at least 1 h at room temperature. The cells were
permeabilized prior to primary antibody incubation. Cells
were then incubated with primary antibodies at 4 °C over-
night and washed three times with PBS. The following
primary antibodies were used in this assay: NANOG
(1:500; ReproCELL, Yokohama, Japan), SSEA4 (1:1,000;
Chemicon, Darmstadt, Germany), βIII-tubulin (1:2,000;
Covance, Princeton, NJ), MAP2 (1:1,000; Millipore, Biller-
ica, MA), SMI-32 (1:2,000; Covance), GFAP (1:1,000;
DAKO, Glostrup, Denmark), TFG (1:1,000; Protein Tech,
Rosemont, IL), Ubiquitin (1:1,000; DAKO), FK2 (1:1,000;
MBL, Nagoya, Japan), SOX17 (1:1,000; R&D Systems,
Minneapolis, MN), and αSMA (1:500; DAKO). Suitable
secondary antibodies (Invitrogen) were incubated with
samples at room temperature for 1 h, and washed three
times with PBS. Nuclear staining was also performed with
0.5 g/mL 4′,6-Diamidino-2-Phenylindole (DAPI) for
5 min, and then the cells were washed three times with
PBS. Coverslips were mounted in ProLong Gold antifade
reagent (Invitrogen). Images were collected using LSM710
(Carl Zeiss, Oberkochen, Germany) or IN Cell Analyzer
6000 (GE Healthcare).
Immunoblot analysis
iPS-MNs of each clone were harvested on Day 35 and
lysed in RIPA buffer [50 mM Tris-HCl buffer, pH 8.0,
0.15 M NaCl, 1% Nonidet P-40 (NP-40), 0.5% sodium
deoxycholate, 0.1% SDS] with protease inhibitor cocktail
(Roche, Basel, Switzerland) and phosphatase inhibitor
(Roche) on ice for 30 min. After sonication with Biorup-
tor (M2 mode, ON: 20 s, OFF: 20 s, 20 times), samples
were centrifuged at 20,000 g for 15 min at 4 °C. The
supernatant was used as sample. Each 10- or 15-μg sam-
ple was subjected to SDS-PAGE (10-20% polyacrylamide
gels, BIO CRAFT, Tokyo, Japan), and separated proteins
were transferred to PVDF. The membranes were incu-
bated with primary antibodies, followed by appropriate
secondary antibodies, and then visualized using ECL
Prime (GE Healthcare, Chicago, IL). The images were
acquired on LAS 4000 (GE Healthcare). The following
primary antibodies were used in this assay: TFG
(1:1,000; Protein Tech), Ubiquitin (1:1,000; DAKO),
cleaved caspase-3 (1:1,000; Cell Signaling Technology,
Danvers, MA), and β-actin (1:5,000; Sigma-Aldrich).
For detection of cleaved caspase-3, iPS-MNs of each
clone were exposed to vehicle or 1 μM MG132 on Day
35 for 24 h. Cells were lysed in RIPA buffer and used for
immunoblot analysis with anti-cleaved caspase-3
antibody.
Purification of MNs using flow cytometry
Production, concentration and infection of HB9::GFP
lentivirus vector were previously reported [17]. All sort-
ing procedures were carried out using FACS Aria II (BD
Biosciences, Franklin Lakes, NJ). After infection with
HB9::GFP lentivirus on Day 20, the differentiated cells
were dissociated into single cells by Accutase and resus-
pended in PBS with 2% FBS and 20 mM D-glucose on
Day 35 for cell sorting. Dead cells were identified by
DAPI staining and excluded from target cells. After
gating optimized for excluding cell doublet HB9::GFP
positive cells and other negative cells, targeted cells were
sorted and plated onto Matrigel-coated 96-well plates at
20,000–30,000 cells/well. Sorted cells were also plated
on a confluent monolayer of primary cortical mouse glia.
Primary glias from P0–P1 mouse pups were prepared as
described previously [41].
Quantitating the area of TFG aggregates in cytoplasm
HB9::GFP-positive MNs or SMI-32-positive neurons
were stained with anti-TFG antibody. The area of TFG
puncta in cytoplasm was quantified by IN Cell Analyzer
6000 (GE Healthcare) and IN CELL Developer toolbox
software 1.92 (GE Healthcare) in randomized 9- or
16-field images in each well.
Cell survival assay
iPS-MNs of each clone on Day 35 were seeded at 3.0 x
104cells per well on Matrigel-coated 96-well plates for
48 h after treatment with DMSO or 10 μM MG132, or
10 nM bortezomib (Selleck Chemicals, Houston, TX).
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The nucleus was stained with DAPI. Each clone was
analyzed using IN Cell Analyzer 6000 (GE Healthcare)
and IN CELL Developer toolbox software 1.92 (GE
Healthcare) in randomized 9-field images in each well.
Cell counts treated with MG132 or bortezomib were nor-
malized to cell counts treated with DMSO in each well.
Analysis of proteasome activity
iPS-MNs of each clone on Day 35 were seeded at 5.0 x
105cells per well on Matrigel-coated 24-well plates.
Whole cell lysates of iPS-MNs were lysed in 0.5% NP-
40. After sonication with Bioruptor (M2 mode, ON:
20 s, OFF: 20 s, 20 times), cell lysates were centrifuged
at 20,000 g for 15 min at 4 °C. The supernatant was used
as sample. Proteasome activity was measured with a
Proteasome Activity Assay Kit (Abcam, Cambridge, UK)
following the manufacturer’s instructions.
Generation of a mutation-corrected clone
For correcting TFG P285L mutation by CRISPR-Cas9, we
designed a guide RNA to target the 5′-CCTAACAGTAA-
GACTAATT-3′ site using CRISPR Design (http://crispr.mi-
t.edu/). The guide RNA oligonucleotide was inserted into
the BamHI-EcoRI site in pHL-H1-ccdB plasmids in order
to express from human H1 polymerase III promoter [12].
We inserted 5′ and 3′ homology arms with normal TFG
gene sequence, and puromycin-resistant cassette flanked by
piggyBac terminal repeats into pBluescript SK (+) for con-
structing the donor plasmid. Their nuclease activity was
validated in 293 T cells by T7E1 method [42]. Target iPSCs
(HMSN-P1) were pretreated with 10 μM Y-27632 (Wako
Chemicals) for 1 h before electroporation. The cells were
washed with PBS and treated with 0.5x TrypLE Select
(Gibco) to dissociate into single cells for 4 min at 37 °C and
were then neutralized with culture medium. Next, we elec-
troporated 10 μg of pHL-H1 guide RNA expression plas-
mids, 10 μg of pHL-EF1α-hcSpCas9 plasmids, and 10 μg of
donor plasmids into 1 x 106 cells using a NEPA 21 electro-
porator (Nepagene, Chiba, Japan). Four days after transfec-
tion, puromycin selection was applied for 10 days.
Surviving colonies were expanded and PCR was used to
confirm proper cassette insertion by PCR using primers A,
B, C, and D (shown in Additional file 4: Table S1). Ampli-
fied PCR bands were further analyzed by Sanger sequen-
cing to confirm the absence of sequence alterations at the
homology arms. To remove the puromycin cassette, 1 x 106
cells were electroporated with 10 μg of piggyBac transpo-
sase expressing vector pHL-EF1α-hcPBase [43]. At 2 days
after electroporation, these cells were passaged. Two days
after passage, colonies were dissociated into single cells and
plated at 200–1000 cells per 100-mm dish. On the follow-
ing day, 1-(2-Deoxy-2-fluoro-β-D-arabinofuranosyl)-5-
iodouracil (FIAU) selection was performed. Surviving col-
onies were expanded and PCR screening was conducted
using primers A, C, and D (Additional file 4: Table S1) for
proper removal of the puromycin cassette. Direct sequen-
cing (3500xL Genetic Analyzer, Applied Biosystems) con-
firmed that the single nucleotide mutation was corrected.
Statistical analysis
All data are shown as mean ± s.e.m. Comparison of two
groups was analyzed using unpaired two-tailed Student’s
t-test or paired t-test. One-way ANOVA was performed
for each comparison, followed by Tukey’s post hoc tests
for evaluation of pairwise group differences. A p-value <
0.05 was considered statistically significant. Analyses
were performed with IBM SPSS statistics software (IBM,
Armonk, NY); *p < 0.05, **p < 0.01.
Additional files
Additional file 1: Figure S1. Global gene expression in iPSC clones and
in vitro three-germ layer assay. (A) HMSN-P patient iPSC clones carried a
TFG P285L mutation. (B) Comparison of global gene expression profiles of
human iPSCs. Heatmap analysis and hierarchical clustering showed that
the global gene expression profiles of control and HMSN-P patient iPSCs
were identical to human embryonic stem cells (H9 ESCs) and different
from HDFs or PBMCs. There are no significant changes in RNA expression
between iPSCs generated from HDFs and PBMCs or those generated by
episomal vectors or retrovirus vectors. HDFs: human dermal fibroblasts,
PBMCs: peripheral blood mononuclear cells. (C) In vitro three-germ layer
assay is shown. Scale bars = 100 μm. Pluripotency of each iPSC clone was
confirmed by in vitro three-germ layer assay. TIG107 was reported
previously [11]. (PDF 1177 kb)
Additional file 2: Figure S2. Evaluation of TFG aggregates in HMSN-P
patient spinal MNs. (A) Immunostaining for TFG in control and HMSN-P
patient SMI-32-positive neurons. Scale bar = 10 μm. (B) Quantification of
area of TFG-positive puncta in SMI-32-positive neurons measured by
high-content analysis (n = 3, n.s. by Student t-test). Error bars are ± s.e.m.
(C) Immunostaining for TFG in purified MNs by HB9::GFP sorting plated
on monolayer of primary cortical mouse glia. Scale bar = 10 μm. (D)
Quantification of area of TFG-positive puncta in purified MNs measured
by high-content analysis (n = 3, n.s. by Student t-test). Error bars are ±
s.e.m. TFG aggregates were not significantly increased in purified MNs
when they were co-cultured with mouse glia. (E) Immunocytochemical
analysis with anti-multi-ubiquitin chain antibody (FK2) using control and
HMSN-P patient iPS-MNs. Aggregations of multi-ubiquitin were
not detected in HMSN-P patient iPS-MNs. (PDF 509 kb)
Additional file 3: Figure S3. Vulnerability of HMSN-P patient iPS-MNs
against UPS inhibitory stress. Survival of control and HMSN-P patient
iPS-MNs after bortezomib exposure (n = 3, **p < 0.01, by Student t-test).
(PDF 222 kb)
Additional file 4: Table S1. Primers used for editing TFG gene.
(DOCX 12 kb)
Abbreviations
2-ME: 2-mercaptoethanol; ALS: Amyotrophic lateral sclerosis; Cas9:
CRISPR associated 9; CRISPR: Clustered regularly interspaced short
palindromic repeat; DAPI: 4′,6-Diamidino-2-Phenylindole; DMSO: Dimethyl
sulfoxide; DSB: Double strand break; EB: Embryoid body; ER: Endoplasmic
reticulum; ESCs: Embryonic stem cells; FIAU: 1-(2-Deoxy-2-fluoro-β-D-
arabinofuranosyl)-5-iodouracil; GFP: Green fluorescent protein; HDFs: Human
dermal fibroblasts; HMSN-P: Hereditary motor and sensory neuropathy with
proximal dominant involvement; HMW: High molecular weight;
iPSCs: Induced pluripotent stem cells; iPS-MNs: Induced pluripotent stem
cells-derived neural cells with spinal motor neurons; MNs: Motor neurons;
mt: Mutant; n.s.: Not significant; P/Q-rich domain: Proline/glutamine-rich
domain; PBMC: Peripheral blood mononuclear cells; PBS: Phosphate-buffered
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saline; TDP-43: TAR DNA-binding protein 43 kDa; TFG: Tropomyosin-receptor
kinase Fused Gene; UPS: Ubiquitin proteasome system
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